Rare Diseases Today—June 4, 2026

This week’s Rare Disease update highlights regulatory milestones, late-stage clinical data, licensing activity, and continued progress across neurology, liver, kidney, and genetic disorders.

In Today’s Newsletter

Dive deeper

💊 Sanofi venglustat priority review [1] [US • 28 May 2026]

https://www.sanofi.com/en/media-room/press-releases/2026/2026-05-28-05-00-00-3302498
Context: LEAP2MONO Phase 3 met both primary endpoints and three of four key secondary endpoints, per Sanofi.
Key point: FDA accepted Sanofi’s venglustat NDA for priority review in type 3 Gaucher disease.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 AstraZeneca anselamimab Phase 3 readout [2] [29 May 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/cares-phase-iii-clinical-programme-did-not-meet-primary-endpoint-in-overall-light-chain-amyloidosis-population.html
Context: Prespecified kappa subgroup showed survival and cardiovascular hospitalization benefits, while lambda subgroup did not.
Key point: CARES Phase 3 did not meet the primary endpoint in the overall AL amyloidosis population.
Implication: May influence prescriber choice and payer reviews pending full data.

⏳ Beren adrabetadex FDA delay [3] [US • 28 May 2026]

https://www.fiercebiotech.com/biotech/fda-extends-berens-rare-disease-review-after-info-request-further-stretching-saga
Context: The agency classified Beren’s response to a data and documentation request as a major amendment.
Key point: FDA delayed its decision on Beren Therapeutics’ adrabetadex for Niemann-Pick disease type C.
Implication: Introduces regulatory timing uncertainty that may affect development and access planning.

🧠 BrainStorm ALS regulatory commentary [4] [US • 02 Jun 2026]

https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-als-rare-diseases-and-regenerative-medicine-302788231.html
Context: The article discusses biomarkers, AI, adaptive designs, Bayesian statistics, and sponsor-regulator alignment.
Key point: BrainStorm announced a publication calling for updated FDA approaches in ALS, rare diseases, and regenerative medicine.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🫀 Mirum rare liver disease data at EASL [5] [EU • 30 May 2026]

https://www.businesswire.com/news/home/20260530475386/en/Mirum-Pharmaceuticals-Announces-New-Data-from-Rare-Liver-Disease-Programs-Presented-at-the-EASL-International-Liver-Congress-2026
Context: VISTAS showed pruritus reductions in PSC, AZURE-1 supported brelovitug in HDV, and LIVMARLI showed improved event-free survival versus an external PFIC cohort.
Key point: Mirum reported EASL data across volixibat in PSC, brelovitug in HDV, and LIVMARLI in PFIC.
Implication: May influence prescriber choice and payer reviews pending full data.

🤝 Everest–Travere civorebrutinib license [6] [02 Jun 2026]

https://www.manilatimes.net/2026/06/02/tmt-newswire/pr-newswire/everest-medicines-enters-into-exclusive-licensing-agreement-with-travere-therapeutics-for-civorebrutinib-a-potential-best-in-class-btk-inhibitor-for-rare-kidney-diseases/2356868
Context: Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor for rare immune-mediated kidney diseases.
Key point: Everest licensed civorebrutinib to Travere for development and commercialization outside China and certain East and Southeast Asian markets.
Implication: Signals pipeline investment and modality expansion.

🧫 Pasithea PAS-004 orphan designation [7] [US • 02 Jun 2026]

https://ir.pasithea.com/news-events/press-releases/detail/141/pasithea-therapeutics-announces-orphan-drug-designation-by
Context: PAS-004 is a next-generation macrocyclic MEK inhibitor; Pasithea previously announced an ALS Association grant.
Key point: FDA granted orphan drug designation to Pasithea’s PAS-004 for ALS.
Implication: May support development incentives and regulatory engagement.

🧴 Quoin QRX003 IND submission [8] [US • 02 Jun 2026]

https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-submits-ind-application-qrx003-peeling
Context: Quoin plans a Phase 2 study in 2H 2026, supported by observations from an investigator-led pediatric study.
Key point: Quoin submitted an IND for QRX003 in peeling skin syndrome.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Rare disease regulatory activity remains active, with priority review, orphan designation, IND submission, and review delay all in one week.
Subgroup evidence is central, especially for AstraZeneca’s anselamimab in kappa AL amyloidosis.
External controls appear in multiple stories, including adrabetadex and LIVMARLI, highlighting evidence-generation challenges.
Business development remains focused on platform-like rare disease assets, as shown by civorebrutinib.
Dermatology, neurology, nephrology, lysosomal storage disease, and liver disease all saw pipeline-relevant updates.

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Rare Disease news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is the key FDA timing for Sanofi’s venglustat?

FDA granted priority review for venglustat in type 3 Gaucher disease. The target action date is 25 Nov 2026. [1]

Did AstraZeneca’s anselamimab succeed in Phase 3?

Not in the overall AL amyloidosis population. The CARES program missed its overall primary endpoint, but the prespecified kappa subgroup showed benefit. [2]

Why was Beren Therapeutics’ adrabetadex review delayed?

FDA classified Beren’s response to a request for data and documentation updates as a major amendment. The decision date moved to 17 Nov 2026. [3]

What did Mirum report at EASL 2026?

Mirum reported data for volixibat in PSC pruritus, brelovitug in HDV, and LIVMARLI in PFIC. The release included clinical efficacy and safety updates. [5]

What is civorebrutinib?

Civorebrutinib is Everest Medicines’ investigational oral, covalent reversible BTK inhibitor. Travere licensed rights for markets outside China and certain East and Southeast Asian countries. [6]

What is QRX003 being developed for now?

Quoin submitted an IND for QRX003 in peeling skin syndrome. It is the second indication for QRX003, in addition to Netherton syndrome. [8]

Entities / Keywords

Sanofi, venglustat, type 3 Gaucher disease, GD3, LEAP2MONO, glucosylceramide synthase inhibitor, GCSi
AstraZeneca, Alexion, anselamimab, CARES Phase 3, AL amyloidosis, kappa light chain amyloidosis, lambda light chain amyloidosis
Beren Therapeutics, adrabetadex, Niemann-Pick disease type C, NPC, cyclodextrin therapy, priority review
BrainStorm Cell Therapeutics, ALS, regenerative medicine, biomarkers, adaptive trial design, Bayesian statistics
Mirum Pharmaceuticals, volixibat, VISTAS, primary sclerosing cholangitis, PSC, brelovitug, AZURE-1, hepatitis delta virus, HDV, LIVMARLI, maralixibat, PFIC
Everest Medicines, Travere Therapeutics, civorebrutinib, EVER001, BTK inhibitor, primary membranous nephropathy, PMN, FSGS, minimal change disease
Pasithea Therapeutics, PAS-004, ALS, MEK inhibitor, orphan drug designation
Quoin Pharmaceuticals, QRX003, peeling skin syndrome, PSS, Netherton syndrome, IND